Pedersen and Maggie Fick COPENHAGEN/LONDON (Reuters) -Obesity drugmaker Novo Nordisk downgraded its 2025 sales forecast on ...

Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast.

Once a dominant force in the weight-loss industry, WW International Inc. (NASDAQ: WW), formerly known as WeightWatchers, is ...

With anti-obesity injections dominating conversations, it's no surprise the conversation around their impact is growing. A ...

The 62-year-old company, which has moved into the prescription drug weight loss business, hopes to emerge from bankruptcy ...

Zepbound is the preferred weight loss medicine vs. Wegovy and has consistently beaten the latter in U.S. weekly prescriptions ...

Shares of Eli Lilly (NYSE: LLY) sank after the drugmaker lowered its full-year profit outlook, and a potential headwind to ...

Hims & Hers Health, Inc.'s Q1 results show 111% growth, yet shares fell 8%. Click for a look at the impact of drug access, ...

Gov. Glenn Youngkin saved about $7 million in state funds and $40 million in federal funds by vetoing a lower body-mass index ...

Physicians describe common prior authorization challenges when treating patients for obesity and share strategies to overcome ...

As summer approaches, millions of Americans are turning to weight-loss injections in hopes of shedding pounds—fast. Roughly ...

However, Wegovy has lost significant market share to rival Eli Lilly‘s (NYSE:LLY) Zepbound, because it is seen as a better, more efficacious GLP-1 drug. Zepbound’s active ingredient, tirzepetide, is ...